EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

EPIDERMAL GROWTH FACTOR EXPRESSION IN PRIMARY PROSTATE CANCER IN PORT HARCOURT, NIGERIA; ASSOCIATION WITH TUMOUR GRADES AND PROSTATE-SPECIFIC ANTIGEN

Monday Komene Sapira* and Ukamaka Chinelo Ogbonnaya

ABSTRACT

Reports in the literature indicate that the Epidermal Growth Factor (EGF) is associated with a worse prognosis of prostate cancer and the development of therapeutic resistance. This study aimed to find out if serum EGF correlates with serum PSA and tumour grade in Port Harcourt. Materials and Methods: All male patients that presented to University of Port Harcourt Teaching Hospital (UPTH), Port Harcourt, Nigeria, were assessed with history, physical examination and laboratory tests. Test included serum PSA full blood count, abdominopelvic ultrasonography transrectal ultrasonography of the prostate. Those with features of prostatic disease had transrectal prostate biopsy done. Each patient’s tumour was graded using the Gleason’s and Grade Group (John Hopkins hospital) systems. Further staging investigations used as indicated were CT scan, CT-urography and pelvic MRI. Serum PSA and epidermal growth factor were measured with ELISA techniques. Results were presented in charts, tables and in prose from. Results: One hundred and four patients (104) had confirmed prostatic tumours. Sixty had benign prostatic hyperplasia. Forty-four (44) had adenocarcinoma of the prostate (PCa). There was a strong correlation between pretreatment serum PSA and serum epidermal growth factor concentrations. The serum EGF expression had a positive correlation with tumour grade up to Gleason 7 (Grade Group grade 3) and after became weakly negative. Conclusion: EGF expression increases with serum PSA and tumour burden. Further tests are necessary to establish the relationship between tumour grade and serum EGF expression. Likely, urinary EGF suggested by others may be more appropriate in predicting PCa grades.

Keywords: Prostate cancer, Level of correlation, Serum epidermal growth factor expression and serum PSA, Tumour grade, Port Harcourt, Nigeria.

[Full Text Article] [Download Certificate]